Introduction: The intensity (loudness)-dependent amplitude change (IDAP) of auditory evoked event-related potential (ERP) components has been suggested as an indicator of central serotonergic neurotransmission. In patients with major depression, associations of high IDAP with favorable SSRI treatment outcome have been reported. This is the first study to assess the predictive value of the IDAP in SNRI treatment. Methods: We evaluated the pre-treatment intensity-dependent change of auditory evoked P1, N1, P2, and P1/N1 and N1/P2 peak-to-peak amplitudes in 14 inpatients with major depressive episode (DSM IV) in the course of 24 days of treatment with the SNRI reboxetine (6-12 mg/d). Results: Our data revealed a highly significant correlation between lower intensity-dependent N1 amplitude slopes prior to reboxetine treatment and stronger decrease of HDRS total score at Fz (r = 0.86, P < 0.001), Fcz (r = 0.91, P < 0.001), and Cz (r = 0.93, P < 0.001). Conclusion: This result corroborates the hypothesis of the IDAP as a differential indicator of serotonergic versus noradrenergic antidepressant psychopharmacotherapy.
References
-
1
Beauducel A, Debener S, Brocke B, Kayser J.
On the Reliability of Augmenting/Reducing.
J Psychophysiol.
2000;
14 (4)
226-240
-
2
Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J.
An inventory for measuring depression.
Arch Gen Psychiatry.
1961;
4
561-571
-
3
Brocke B, Beauducel A, John R, Debener S, Heilemann H.
Sensation seeking and affective disorders: characteristics in the intensity dependence of acoustic evoked potentials.
Neuropsychobiology.
2000;
41
24-30
-
4
Buchsbaum M, Silverman J.
Stimulus intensity control and the cortical evoked response.
Psychosom Med.
1968;
30
12-22
-
5
Croft R J, Klugman A, Baldeweg T, Gruzelier J H.
Electrophysiological evidence of serotonergic impairment in long-term MDMA (”ecstasy”) users.
Am J Psychiatry.
2001;
158
1687-1692
-
6
Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss H J, Mavrogiorgou P, Hegerl U.
The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression.
Psychopharmacology (Berl).
2000;
148
404-411
-
7
Gallinat J, Senkowski D, Wernicke C, Juckel G, Becker I, Sander T, Smolka M, Hegerl U, Rommelspacher H, Winterer G, Herrmann W M.
Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing.
Neuropsychopharmacology.
2003;
28
530-532
-
8
Hamilton M.
A rating scale for depression.
J Neurol Neurosurg Psychiatry.
1960;
23
56-62
-
9
Hegerl U, Bottlender R, Gallinat J, Kuss H J, Ackenheil M, Moller H J.
The serotonin syndrome scale: first results on validity.
Eur Arch Psychiatry Clin Neurosci.
1998;
248
96-103
-
10
Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S.
The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.
Pharmacopsychiatry.
2004;
37
200-205
-
11
Juckel G, Hegerl U, Molnar M, Csepe V, Karmos G.
Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus.
Neuropsychopharmacology.
1999;
21
710-716
-
12
Juckel G, Mavrogiorgou P, Bredemeier S, Gallinat J, Frodl T, Schulz C, Moller H J, Hegerl U.
Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders - a retrospective study.
Pharmacopsychiatry.
2004;
37
46-51
-
13
Kuenzel H E, Murck H, Held K, Ziegenbein M, Steiger A.
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Pharmacopsychiatry.
2004;
37
193-195
-
14 Linka T, Müller B W, Bender S, Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor to Citalopram treatment in patients with major depression. Neuroscience Letters 2004: in press
-
15
Mulert C, Jager L, Pogarell O, Bussfeld P, Schmitt R, Juckel G, Hegerl U.
Simultaneous ERP and event-related fMRI: focus on the time course of brain activity in target detection.
Methods Find Exp Clin Pharmacol.
2002;
24Suppl D
17-20
-
16 (NIMH) N IoMH. CGI. Glinical global impressions. In: Bonato R, ed Manual for the EDCEU assessment battery,. 2nd edition Vol. 12 (R. Bonato, ed) NIMH, Chevy Chase; 1976
-
17
Owens M J.
Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond.
J Clin Psychiatry.
2004;
65 Suppl 4
5-10
-
18
Paige S R, Fitzpatrick D F, Kline J P, Balogh S E, Hendricks S E.
Event-related potential amplitude/intensity slopes predict response to antidepressants.
Neuropsychobiology.
1994;
30
197-201
-
19
Proietti-Cecchini A, Afra J, Schoenen J.
Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
Cephalalgia.
1997;
17
849-854; discussion 799
-
20 Quednow B B, Kuhn K U, Stelzenmueller R, Hoenig K, Maier W, Wagner M. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology (Berl) 2004
-
21
Semlitsch H V, Anderer P, Schuster P, Presslich O.
A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP.
Psychophysiology.
1986;
23
695-703
-
22
Strobel A, Debener S, Schmidt D, Hunnerkopf R, Lesch K P, Brocke B.
Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential.
Am J Med Genet.
2003;
118B
41-47
-
23
Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E.
High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users.
Neuropsychopharmacology.
2000;
22
608-617
-
24
von Knorring L, Johansson F.
Changes in the augmenter-reducer tendency and in pain measures as a result of treatment with a serotonin-reuptake inhibitor - zimelidine.
Neuropsychobiology.
1980;
6
313-318
-
25
von Knorring L, Perris C.
Biochemistry of the augmenting-reducing response in visual evoked potentials.
Neuropsychobiology.
1981;
7
1-8
-
26
Wang W, Timsit-Berthier M, Schoenen J.
Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission?.
Neurology.
1996;
46
1404-1409
-
27
Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff C B.
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
Am J Psychiatry.
2004;
161
1575-1580
Thomas Linka, MD
Clinic for Psychiatry and Psychotherapy
University of Duisburg-Essen
Virchowstrasse 174
45147 Essen
Germany
Telefon: +49 201 7227 226
Fax: +49 201 7227 303
eMail: thomas.linka@uni-essen.de
